GP
Therapeutic Areas
Lixte Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LB-100 + Dostarlimab | Ovarian Clear Cell Carcinoma (OCCC) | Phase 2 |
| LB-100 + Immunotherapy | Advanced Soft Tissue Sarcoma | Not Specified |
| Drug | Indication | Phase |
|---|---|---|
| LB-100 + Dostarlimab | Ovarian Clear Cell Carcinoma (OCCC) | Phase 2 |
| LB-100 + Immunotherapy | Advanced Soft Tissue Sarcoma | Not Specified |